TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $6,866,240.40 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the sale, the insider now directly owns 9,792 shares in the company, valued at $1,062,823.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded up $3.55 during mid-day trading on Friday, reaching $127.99. The company’s stock had a trading volume of 1,543,089 shares, compared to its average volume of 765,449. The stock has a 50-day moving average of $85.54 and a two-hundred day moving average of $76.85. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The stock has a market capitalization of $4.19 billion, a P/E ratio of -376.44 and a beta of 1.87. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $129.66.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. TransMedics Group’s revenue was up 132.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.08) EPS. On average, equities research analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new stake in shares of TransMedics Group in the 1st quarter worth $30,000. Fidelis Capital Partners LLC acquired a new stake in TransMedics Group during the first quarter worth about $35,000. Cutler Group LLC CA raised its stake in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares during the period. RiverPark Advisors LLC purchased a new position in TransMedics Group during the third quarter worth about $60,000. Finally, First Horizon Advisors Inc. boosted its holdings in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research note on Wednesday. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. Oppenheimer increased their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, TD Cowen upped their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.